AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01634048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein, low calorie meal replacement
Description: The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
Study NCT01634048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: High Protein, low calorie meal replacement
Description: The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
Study NCT05333601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSCCIP
Description: The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
Study NCT01102868 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Needle in acupuncture point Li11
Description: Acupuncture needle in acupuncture point Li11
Study NCT01102868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMS of the musculus pronator teres
Description: Acupuncture needle in musculus pronator teres
Study NCT04225234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes.
Study NCT04225234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentives
Description: Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes.
Study NCT04174378 — intervention group
Intervention type: DRUG
Intervention: Decapeptyl 0.2mg
Description: IM Decapeptyl o.2 mg was given 2 days before embryo transfer
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill daily starting one day prior to surgery until discharge from the hospital.
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study NCT00167583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
Study NCT00167583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha2a
Description: 3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
Study NCT00472095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fotonovela
Study NCT03510039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early device / Follow up
Description: Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call
Study NCT03510039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Group Before : usual care by nurses
Study NCT02409199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00472095 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fotonovela
Study NCT02409199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Study NCT01343810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
Study NCT01343810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: Patients that required continuous insulin infusion (CII) at a rate >1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between >180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG >241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patients that required continuous insulin infusion (CII) at a rate >1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between >180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG >241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal
Study NCT01343810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
Study NCT01343810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
Study NCT02934698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
Study NCT04443946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Study NCT04443946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Study NCT04443946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Sevoflurane
Description: add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
Study NCT04443946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Sevoflurane continue
Description: 1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
Study NCT04443946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
Study NCT04443946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Sevoflurane
Description: 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
Study NCT04443946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol half
Description: 2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Study NCT01560234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Single dose, oral inhalation (nebuliser solution)
Study NCT01560234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral inhalation (nebuliser solution)
Study NCT03929120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Description: Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
Study NCT00730535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: Extended release tolterodine tartrate 4 mg, once daily, for 1 months
Study NCT00730535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: Extended release tolterodine tartrate 4 mg, once daily, for 3 months
Study NCT00730535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine 6
Description: Extended release tolterodine tartrate 4 mg, once daily, for 6 months
Study NCT04519268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adult patients scheduled for an elective general surgical operation.
Description: The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) \& consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations \& required preparations, peri-operative course and post-operative outcome will be collected.
Study NCT04033731 — intervention group
Intervention type: BEHAVIORAL
Intervention: Attention Network Task
Description: The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
Study NCT01509313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hysteroscopic morcellator (TruClear)
Description: It can be used to treat uterine pathology with a mechanical cutting edge
Study NCT01509313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Electrical resectoscope (Versapoint)
Description: It can be used to treat uterine pathology with an electrical cutting edge
Study NCT03510845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL Primary Repair
Description: All patients (in both groups) will undergo diagnostic knee arthroscopy at the start of the procedure; those in the experimental arm repairable ACL tear, whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental insulin (Insulin lispro)
Description: Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin (Insulin lispro)
Description: Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental insulin (Insulin aspart)
Description: Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart
Study NCT02556918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental insulin (Insulin aspart)
Description: Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart
Study NCT03510845 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic ACL Reconstruction
Description: Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
Study NCT03023618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FloTrac
Description: Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
Study NCT01270984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luckyvec 400mg film coated tablet
Description: •400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
Study NCT01270984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glivec 100mg film coated tablet
Description: •100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)
Study NCT00833495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 0.12% (Pred Mild®)
Description: Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.